{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T06:04:44Z","timestamp":1791266684361,"version":"4.1.0"},"reference-count":132,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T00:00:00Z","timestamp":1748822400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T00:00:00Z","timestamp":1748822400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-025-02788-0","type":"journal-article","created":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T18:50:44Z","timestamp":1748890244000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Targeting endothelial growth factor receptor in thyroid cancer: current concepts and future directions"],"prefix":"10.1007","volume":"42","author":[{"given":"Nastaran","family":"Masoudi-Khoram","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Cheraghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahboobeh","family":"Nazari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad E.","family":"Khamseh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,2]]},"reference":[{"issue":"3","key":"2788_CR1","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clini. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clini"},{"issue":"1","key":"2788_CR2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12889-020-10013-y","volume":"21","author":"Y Cui","year":"2021","unstructured":"Cui Y, Mubarik S, Li R, Yu C. Trend dynamics of thyroid cancer incidence among China and the US adult population from 1990 to 2017: a joinpoint and age-period-cohort analysis. BMC Public Health. 2021;21(1):1\u201313.","journal-title":"BMC Public Health"},{"issue":"3","key":"2788_CR3","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.21873\/anticanres.14883","volume":"41","author":"HK Lee","year":"2021","unstructured":"Lee HK, Noh MH, Hong SW, Kim SM, Kim SH, Kim YS, Broaddus VC, Hur DY. Erlotinib activates different cell death pathways in EGFR-mutant lung cancer cells grown in 3D versus 2D culture systems. Anticancer Res. 2021;41(3):1261\u20139.","journal-title":"Anticancer Res"},{"issue":"6","key":"2788_CR4","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.3390\/ijms22063117","volume":"22","author":"L Lorusso","year":"2021","unstructured":"Lorusso L, Cappagli V, Valerio L, Giani C, Viola D, Puleo L, Gambale C, Minaldi E, Campopiano MC, Matrone A. Thyroid cancers: from surgery to current and future systemic therapies through their molecular identities. Int J Mol Sci. 2021;22(6):3117.","journal-title":"Int J Mol Sci"},{"key":"2788_CR5","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/978-3-031-35213-3_7","volume-title":"Integrated diagnostics and theranostics of thyroid diseases","author":"AM Avram","year":"2023","unstructured":"Avram AM. Radioiodine theranostics of differentiated thyroid carcinoma. In: Integrated diagnostics and theranostics of thyroid diseases. Cham: Springer International Publishing; 2023. p. 111\u201327."},{"issue":"3","key":"2788_CR6","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/ajco.13836","volume":"19","author":"Q Yu","year":"2023","unstructured":"Yu Q, Zhang X, Li L, Zhang C, Huang J, Huang W. Molecular basis and targeted therapies for radioiodine refractory thyroid cancer. Asia Pac J Clin Oncol. 2023;19(3):279\u201389.","journal-title":"Asia Pac J Clin Oncol"},{"issue":"4","key":"2788_CR7","doi-asserted-by":"crossref","first-page":"R185","DOI":"10.1530\/ERC-15-0555","volume":"23","author":"D Viola","year":"2016","unstructured":"Viola D, Valerio L, Molinaro E, Agate L, Bottici V, Biagini A, Lorusso L, Cappagli V, Pieruzzi L, Giani C. Treatment of advanced thyroid cancer with targeted therapies: ten years of experience. Endocr Relat Cancer. 2016;23(4):R185-205.","journal-title":"Endocr Relat Cancer"},{"issue":"10","key":"2788_CR8","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1038\/s12276-022-00864-3","volume":"54","author":"H-Y Min","year":"2022","unstructured":"Min H-Y, Lee H-Y. Molecular targeted therapy for anticancer treatment. Exp Mol Med. 2022;54(10):1670\u201394.","journal-title":"Exp Mol Med"},{"issue":"2","key":"2788_CR9","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.3390\/ijms25021064","volume":"25","author":"E Rubin","year":"2024","unstructured":"Rubin E, Shan KS, Dalal S, Vu DUD, Milillo-Naraine AM, Guaqueta D, Ergle A. Molecular targeting of the human epidermal growth factor receptor-2 (HER2) genes across various cancers. Int J Mol Sci. 2024;25(2):1064.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"2788_CR10","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.3390\/molecules26041076","volume":"26","author":"NEM Kaufman","year":"2021","unstructured":"Kaufman NEM, Dhingra S, Jois SD. Vicente MdGH: molecular targeting of epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor (VEGFR). Molecules. 2021;26(4):1076.","journal-title":"Molecules"},{"issue":"4","key":"2788_CR11","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.3390\/molecules26041076","volume":"26","author":"NEM Kaufman","year":"2021","unstructured":"Kaufman NEM, Dhingra S, Jois SD, Vicente MDGH. Molecular targeting of epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor (VEGFR). Molecules. 2021;26(4):1076.","journal-title":"Molecules"},{"issue":"13","key":"2788_CR12","doi-asserted-by":"crossref","first-page":"11110","DOI":"10.3390\/ijms241311110","volume":"24","author":"SMB Rodriguez","year":"2023","unstructured":"Rodriguez SMB, Kamel A, Ciubotaru GV, Onose G, Sevastre AS, Sfredel V, Danoiu S, Dricu A, Tataranu LG. An overview of EGFR mechanisms and their implications in targeted therapies for glioblastoma. Int J Mol Sci. 2023;24(13):11110.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"2788_CR13","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3390\/cancers9040033","volume":"9","author":"N Jacobi","year":"2017","unstructured":"Jacobi N, Seeboeck R, Hofmann E, Eger A. ErbB family signalling: a paradigm for oncogene addiction and personalized oncology. Cancers. 2017;9(4):33.","journal-title":"Cancers"},{"key":"2788_CR14","first-page":"101490","volume":"7","author":"R Mariam Raju","year":"2024","unstructured":"Mariam Raju R, Joy AJ, Nulgumnalli Manjunathaiah R, Justin A, Prashantha Kumar BR. EGFR as therapeutic target to develop new generation tyrosine kinase inhibitors against breast cancer: a critical review. Res Chem. 2024;7:101490.","journal-title":"Res Chem"},{"issue":"3","key":"2788_CR15","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3390\/biom14030259","volume":"14","author":"D Wang","year":"2024","unstructured":"Wang D, Liu G, Meng Y, Chen H, Ye Z, Jing J. The configuration of GRB2 in protein interaction and signal transduction. Biomolecules. 2024;14(3):259.","journal-title":"Biomolecules"},{"key":"2788_CR16","doi-asserted-by":"crossref","first-page":"116771","DOI":"10.1016\/j.ejmech.2024.116771","volume":"277","author":"D Pandey","year":"2024","unstructured":"Pandey D, Chauhan SC, Kashyap VK, Roy KK. Structural insights into small-molecule KRAS inhibitors for targeting KRAS mutant cancers. Eur J Med Chem. 2024;277:116771.","journal-title":"Eur J Med Chem"},{"issue":"6","key":"2788_CR17","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1002\/prot.24805","volume":"83","author":"A Kapoor","year":"2015","unstructured":"Kapoor A, Travesset A. Differential dynamics of RAS isoforms in GDP-and GTP-bound states. Proteins Struct Funct Bioinf. 2015;83(6):1091\u2013106.","journal-title":"Proteins Struct Funct Bioinf"},{"issue":"46","key":"2788_CR18","doi-asserted-by":"crossref","first-page":"18519","DOI":"10.1073\/pnas.1318188110","volume":"110","author":"X Nan","year":"2013","unstructured":"Nan X, Collisson EA, Lewis S, Huang J, Tamg\u00fcney TM, Liphardt JT, McCormick F, Gray JW, Chu S. Single-molecule superresolution imaging allows quantitative analysis of RAF multimer formation and signaling. Proc Natl Acad Sci. 2013;110(46):18519\u201324.","journal-title":"Proc Natl Acad Sci"},{"issue":"4","key":"2788_CR19","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.molcel.2012.12.018","volume":"49","author":"AK Freeman","year":"2013","unstructured":"Freeman AK, Ritt DA, Morrison DK. Effects of Raf dimerization and its inhibition on normal and disease-associated Raf signaling. Mol Cell. 2013;49(4):751\u20138.","journal-title":"Mol Cell"},{"issue":"1","key":"2788_CR20","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/s41467-022-28084-3","volume":"13","author":"JA Martinez Fiesco","year":"2022","unstructured":"Martinez Fiesco JA, Durrant DE, Morrison DK, Zhang P. Structural insights into the BRAF monomer-to-dimer transition mediated by RAS binding. Nat Commun. 2022;13(1):486.","journal-title":"Nat Commun"},{"issue":"5","key":"2788_CR21","doi-asserted-by":"crossref","first-page":"97","DOI":"10.4251\/wjgo.v5.i5.97","volume":"5","author":"K Zenonos","year":"2013","unstructured":"Zenonos K, Kyprianou K. RAS signaling pathways, mutations and their role in colorectal cancer. World J Gastroint Oncol. 2013;5(5):97.","journal-title":"World J Gastroint Oncol"},{"key":"2788_CR22","doi-asserted-by":"crossref","first-page":"817916","DOI":"10.3389\/fonc.2022.817916","volume":"12","author":"R Huang","year":"2022","unstructured":"Huang R, Dai Q, Yang R, Duan Y, Zhao Q, Haybaeck J, Yang Z. A review: PI3K\/AKT\/mTOR signaling pathway and its regulated eukaryotic translation initiation factors may be a potential therapeutic target in esophageal squamous cell carcinoma. Front Oncol. 2022;12:817916.","journal-title":"Front Oncol"},{"issue":"1","key":"2788_CR23","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s13045-020-00949-4","volume":"13","author":"J Yuan","year":"2020","unstructured":"Yuan J, Dong X, Yap J, Hu J. The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy. J Hematol Oncol. 2020;13(1):113.","journal-title":"J Hematol Oncol"},{"issue":"11","key":"2788_CR24","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1136\/jcp.2006.040105","volume":"60","author":"LR Rowe","year":"2007","unstructured":"Rowe LR, Bentz BG, Bentz JS. Detection of BRAF V600E activating mutation in papillary thyroid carcinoma using PCR with allele-specific fluorescent probe melting curve analysis. J Clin Pathol. 2007;60(11):1211\u20135.","journal-title":"J Clin Pathol"},{"issue":"7","key":"2788_CR25","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1093\/carcin\/bgp337","volume":"31","author":"TS Niault","year":"2010","unstructured":"Niault TS, Baccarini M. Targets of Raf in tumorigenesis. Carcinogenesis. 2010;31(7):1165\u201374.","journal-title":"Carcinogenesis"},{"issue":"10","key":"2788_CR26","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1200\/JCO.2010.32.4327","volume":"29","author":"GV Long","year":"2011","unstructured":"Long GV, Menzies AM, Nagrial AM, Haydu LE, Hamilton AL, Mann GJ, Hughes TM, Thompson JF, Scolyer RA, Kefford RF. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol. 2011;29(10):1239\u201346.","journal-title":"J Clin Oncol"},{"key":"2788_CR27","first-page":"e1291","volume":"6","author":"C Santonastaso","year":"2019","unstructured":"Santonastaso C, Di Paolo M, Tommaselli A, Morelli L, Pugliese S, Troisi A, Muto T, Di Martino S. A simple and high sensitive method for detection of B-RAF 1799T> A (V600E) mutation in the thyroid fine needle aspirate. World Cancer Res J. 2019;6:e1291.","journal-title":"World Cancer Res J"},{"issue":"1","key":"2788_CR28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1515\/oncologie-2022-1030","volume":"25","author":"T Zablocka","year":"2023","unstructured":"Zablocka T, Kreismane M, Pjanova D, Isajevs S. Effects of BRAF V600E and NRAS mutational status on the progression-free survival and clinicopathological characteristics of patients with melanoma. Oncol Lett. 2023;25(1):1\u20139.","journal-title":"Oncol Lett"},{"issue":"5","key":"2788_CR29","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.3390\/cancers13051139","volume":"13","author":"E Macerola","year":"2021","unstructured":"Macerola E, Poma AM, Vignali P, Basolo A, Ugolini C, Torregrossa L, Santini F, Basolo F. Molecular genetics of follicular-derived thyroid cancer. Cancers. 2021;13(5):1139.","journal-title":"Cancers"},{"issue":"3","key":"2788_CR30","first-page":"e276","volume":"1","author":"A De Monaco","year":"2014","unstructured":"De Monaco A, Faioli D, Di Paolo M, Catapano O, D\u2019Orta A, Del Buono M, Del Buono R, Di Francia R. Pharmacogenomics markers for prediction response and toxicity in cancer therapy. WCRJ. 2014;1(3):e276.","journal-title":"WCRJ"},{"issue":"11","key":"2788_CR31","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/nrm1498","volume":"5","author":"C Wellbrock","year":"2004","unstructured":"Wellbrock C, Karasarides M, Marais R. The RAF proteins take centre stage. Nat Rev Mol Cell Biol. 2004;5(11):875\u201385.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"3","key":"2788_CR32","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1172\/JCI85271","volume":"126","author":"I Landa","year":"2016","unstructured":"Landa I, Ibrahimpasic T, Boucai L, Sinha R, Knauf JA, Shah RH, Dogan S, Ricarte-Filho JC, Krishnamoorthy GP, Xu B. Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. J Clin Investig. 2016;126(3):1052\u201366.","journal-title":"J Clin Investig"},{"issue":"11","key":"2788_CR33","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.3390\/genes11111342","volume":"11","author":"M \u015amiech","year":"2020","unstructured":"\u015amiech M, Leszczy\u0144ski P, Kono H, Wardell C, Taniguchi H. Emerging BRAF mutations in cancer progression and their possible effects on transcriptional networks. Genes. 2020;11(11):1342.","journal-title":"Genes"},{"issue":"3","key":"2788_CR34","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/nrc3431","volume":"13","author":"M Xing","year":"2013","unstructured":"Xing M. Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer. 2013;13(3):184\u201399.","journal-title":"Nat Rev Cancer"},{"key":"2788_CR35","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.isci.2019.09.030","volume":"20","author":"R Ciampi","year":"2019","unstructured":"Ciampi R, Romei C, Ramone T, Prete A, Tacito A, Cappagli V, Bottici V, Viola D, Torregrossa L, Ugolini C. Genetic landscape of somatic mutations in a large cohort of sporadic medullary thyroid carcinomas studied by next-generation targeted sequencing. IScience. 2019;20:324\u201336.","journal-title":"IScience"},{"issue":"1","key":"2788_CR36","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13044-023-00181-5","volume":"16","author":"M Kabootari","year":"2023","unstructured":"Kabootari M, Habibi Tirtashi R, Zadeh-Vakili A, Zarkesh M, Samadanifard H, Haghighi S, Azizi F, Amouzegar A. RET\/PTC rearrangement in papillary thyroid carcinoma arising in malignant struma ovarii with abdominal wall metastasis and cervical thyroid gland: a case report and review of the literature. Thyroid Res. 2023;16(1):39.","journal-title":"Thyroid Res"},{"issue":"7","key":"2788_CR37","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.3390\/ijms17071093","volume":"17","author":"F Steiner","year":"2016","unstructured":"Steiner F, Hauser-Kronberger C, Rendl G, Rodrigues M, Pirich C. Expression of tenascin C, EGFR, E-cadherin, and TTF-1 in medullary thyroid carcinoma and the correlation with RET mutation status. Int J Mol Sci. 2016;17(7):1093.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"2788_CR38","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1158\/1078-0432.CCR-20-3208","volume":"27","author":"S-R Yang","year":"2021","unstructured":"Yang S-R, Aypar U, Rosen EY, Mata DA, Benayed R, Mullaney K, Jayakumaran G, Zhang Y, Frosina D, Drilon A. A performance comparison of commonly used assays to detect RET fusions. Clin Cancer Res. 2021;27(5):1316\u201328.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"2788_CR39","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1210\/clinem\/dgac325","volume":"107","author":"R Elisei","year":"2022","unstructured":"Elisei R, Ciampi R, Matrone A, Prete A, Gambale C, Ramone T, Simeakis G, Materazzi G, Torregrossa L, Ugolini C. Somatic RET indels in sporadic medullary thyroid cancer: prevalence and response to selpercatinib. J Clin Endocrinol Metab. 2022;107(8):2195\u2013202.","journal-title":"J Clin Endocrinol Metab"},{"key":"2788_CR40","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.2147\/OTT.S305196","volume":"14","author":"L Gui","year":"2021","unstructured":"Gui L, Liu S, Zhang Y, Shi Y. A remarkable and durable response to sintilimab and anlotinib in the first-line treatment of an anaplastic thyroid carcinoma without targetable genomic alterations: a case report. OncoTarg Ther. 2021;14:2741\u20136.","journal-title":"OncoTarg Ther"},{"issue":"11","key":"2788_CR41","doi-asserted-by":"crossref","first-page":"4183","DOI":"10.1158\/0008-5472.CAN-08-0413","volume":"68","author":"M Croyle","year":"2008","unstructured":"Croyle M, Akeno N, Knauf JA, Fabbro D, Chen X, Baumgartner JE, Lane HA, Fagin JA. RET\/PTC-induced cell growth is mediated in part by epidermal growth factor receptor (EGFR) activation: evidence for molecular and functional interactions between RET and EGFR. Can Res. 2008;68(11):4183\u201391.","journal-title":"Can Res"},{"key":"2788_CR42","doi-asserted-by":"crossref","first-page":"102","DOI":"10.3389\/fendo.2020.00102","volume":"11","author":"A Prete","year":"2020","unstructured":"Prete A, Borges de Souza P, Censi S, Muzza M, Nucci N, Sponziello M. Update on fundamental mechanisms of thyroid cancer. Front Endocrinol. 2020;11:102.","journal-title":"Front Endocrinol"},{"issue":"4","key":"2788_CR43","doi-asserted-by":"crossref","first-page":"284","DOI":"10.14740\/jocmr2480w","volume":"8","author":"S Jin","year":"2016","unstructured":"Jin S, Borkhuu O, Bao W, Yang YT. Signaling pathways in thyroid cancer and their therapeutic implications. J Clin Med Res. 2016;8(4):284\u201396.","journal-title":"J Clin Med Res"},{"key":"2788_CR44","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1176731","author":"S Hamidi","year":"2023","unstructured":"Hamidi S, Hofmann M-C, Iyer PC, Cabanillas ME, Hu MI, Busaidy NL, Dadu R. Review article: new treatments for advanced differentiated thyroid cancers and potential mechanisms of drug resistance. Front Endocrinol. 2023. https:\/\/doi.org\/10.3389\/fendo.2023.1176731.","journal-title":"Front Endocrinol"},{"key":"2788_CR45","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00800","author":"R Thomas","year":"2019","unstructured":"Thomas R, Weihua Z. Rethink of EGFR in cancer with its kinase independent function on board. Front Oncol. 2019. https:\/\/doi.org\/10.3389\/fonc.2019.00800.","journal-title":"Front Oncol"},{"issue":"1","key":"2788_CR46","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jss.2013.05.003","volume":"185","author":"KE Fisher","year":"2013","unstructured":"Fisher KE, Jani JC, Fisher SB, Foulks C, Hill CE, Weber CJ, Cohen C, Sharma J. Epidermal growth factor receptor overexpression is a marker for adverse pathologic features in papillary thyroid carcinoma. J Surg Res. 2013;185(1):217\u201324.","journal-title":"J Surg Res"},{"issue":"1","key":"2788_CR47","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1186\/s13104-022-06260-4","volume":"15","author":"DS Heriyanto","year":"2022","unstructured":"Heriyanto DS, Laiman V, Limantara NV, Anantawikrama WP, Yuliani FS, Cempaka R, Anwar SL. High frequency of KRAS and EGFR mutation profiles in BRAF-negative thyroid carcinomas in Indonesia. BMC Res Notes. 2022;15(1):369.","journal-title":"BMC Res Notes"},{"issue":"1","key":"2788_CR48","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1677\/ERC-08-0304","volume":"17","author":"C Rodr\u00edguez-Antona","year":"2010","unstructured":"Rodr\u00edguez-Antona C, Pallares J, Montero-Conde C, Inglada-P\u00e9rez L, Castelblanco E, Landa I, Leskel\u00e4 S, Leandro-Garc\u00eda LJ, L\u00f3pez-Jim\u00e9nez E, Let\u00f3n R. Overexpression and activation of EGFR and VEGFR2 in medullary thyroid carcinomas is related to metastasis. Endocr Relat Cancer. 2010;17(1):7\u201316.","journal-title":"Endocr Relat Cancer"},{"key":"2788_CR49","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1385\/ENDO:30:1:129","volume":"30","author":"S Hoffmann","year":"2006","unstructured":"Hoffmann S, Maschuw K, Hassan I, Wunderlich A, Lingelbach S, Ramaswamy A, Hofbauer L, Zielke A. Functional thyrotropin receptor attenuates malignant phenotype of follicular thyroid cancer cells. Endocrine. 2006;30:129\u201338.","journal-title":"Endocrine"},{"key":"2788_CR50","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s12020-007-0008-9","volume":"31","author":"S Hoffmann","year":"2007","unstructured":"Hoffmann S, Burchert A, Wunderlich A, Wang Y, Lingelbach S, Hofbauer L, Rothmund M, Zielke A. Differential effects of cetuximab and AEE 788 on epidermal growth factor receptor (EGF-R) and vascular endothelial growth factor receptor (VEGF-R) in thyroid cancer cell lines. Endocrine. 2007;31:105\u201313.","journal-title":"Endocrine"},{"key":"2788_CR51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11912-020-00997-6","volume":"23","author":"I Abe","year":"2021","unstructured":"Abe I. Anaplastic thyroid carcinoma: current issues in genomics and therapeutics. Curr Oncol Rep. 2021;23:1\u201314.","journal-title":"Curr Oncol Rep"},{"issue":"3","key":"2788_CR52","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1177\/0300060513477312","volume":"41","author":"YM Lee","year":"2013","unstructured":"Lee YM, Lee JB. Prognostic value of epidermal growth factor receptor, p53 and galectin-3 expression in papillary thyroid carcinoma. J Int Med Res. 2013;41(3):825\u201334.","journal-title":"J Int Med Res"},{"issue":"4","key":"2788_CR53","doi-asserted-by":"crossref","first-page":"228","DOI":"10.16956\/jes.2018.18.4.228","volume":"18","author":"Y-S Kim","year":"2018","unstructured":"Kim Y-S, Kim J-S, Kim Y-S. EGFR and HER2 expression in papillary thyroid carcinoma. J Endocr Surg. 2018;18(4):228\u201335.","journal-title":"J Endocr Surg"},{"issue":"11","key":"2788_CR54","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1002\/ijc.24250","volume":"124","author":"K Masago","year":"2009","unstructured":"Masago K, Asato R, Fujita S, Hirano S, Tamura Y, Kanda T, Mio T, Katakami N, Mishima M, Ito J. Epidermal growth factor receptor gene mutations in papillary thyroid carcinoma. Int J Cancer. 2009;124(11):2744\u20139.","journal-title":"Int J Cancer"},{"key":"2788_CR55","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.humpath.2016.10.020","volume":"61","author":"J Jankovi\u0107","year":"2017","unstructured":"Jankovi\u0107 J, Tati\u0107 S, Bo\u017ei\u0107 V, \u017divaljevi\u0107 V, Cveji\u0107 D, Paska\u0161 S. Inverse expression of caveolin-1 and EGFR in thyroid cancer patients. Hum Pathol. 2017;61:164\u201372.","journal-title":"Hum Pathol"},{"issue":"1","key":"2788_CR56","doi-asserted-by":"crossref","first-page":"36","DOI":"10.4103\/1817-1737.197774","volume":"12","author":"SY Kim","year":"2017","unstructured":"Kim SY, Kim H-R, Kim CH, Koh JS, Baek HJ, Choi C-M, Song JS, Lee JC, Na II. Association between thyroid cancer and epidermal growth factor receptor mutation in female with nonsmall cell lung cancer. Ann Thor Med. 2017;12(1):36\u201341.","journal-title":"Ann Thor Med"},{"issue":"1","key":"2788_CR57","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.humpath.2007.05.012","volume":"39","author":"DD Elliott","year":"2008","unstructured":"Elliott DD, Sherman SI, Busaidy NL, Williams MD, Santarpia L, Clayman GL, El-Naggar AK. Growth factor receptors expression in anaplastic thyroid carcinoma: potential markers for therapeutic stratification. Hum Pathol. 2008;39(1):15\u201320.","journal-title":"Hum Pathol"},{"issue":"11","key":"2788_CR58","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1038\/nrc1953","volume":"6","author":"MK Nyati","year":"2006","unstructured":"Nyati MK, Morgan MA, Feng FY, Lawrence TS. Integration of EGFR inhibitors with radiochemotherapy. Nat Rev Cancer. 2006;6(11):876\u201385.","journal-title":"Nat Rev Cancer"},{"key":"2788_CR59","first-page":"8","volume":"2015","author":"J Michael","year":"2015","unstructured":"Michael J, Greig SN, Weinrich SL, Feng JL, Shi M, Johnson TO. Effects of activating mutations on EGFR cellular protein turnover and amino acid recycling determined using SILAC mass spectrometry. Int J Cell Biol. 2015;2015:8.","journal-title":"Int J Cell Biol"},{"issue":"11","key":"2788_CR60","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3390\/cells7110212","volume":"7","author":"T Nagano","year":"2018","unstructured":"Nagano T, Tachihara M, Nishimura Y. Mechanism of resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and a potential treatment strategy. Cells. 2018;7(11):212.","journal-title":"Cells"},{"issue":"3","key":"2788_CR61","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/nm.4040","volume":"22","author":"AN Hata","year":"2016","unstructured":"Hata AN, Niederst MJ, Archibald HL, Gomez-Caraballo M, Siddiqui FM, Mulvey HE, Maruvka YE, Ji F. Bhang H-eC, Krishnamurthy Radhakrishna V: Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition. Nat Med. 2016;22(3):262\u20139.","journal-title":"Nat Med"},{"issue":"11","key":"2788_CR62","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/nrc3106","volume":"11","author":"Y Pylayeva-Gupta","year":"2011","unstructured":"Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D. RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer. 2011;11(11):761\u201374.","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"2788_CR63","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1634\/theoncologist.2013-0072","volume":"18","author":"GM Howell","year":"2013","unstructured":"Howell GM, Hodak SP, Yip L (2013) RAS mutations in thyroid cancer. Oncologist 18(8):926\u201332. https:\/\/doi.org\/10.1634\/theoncologist.2013-0072","journal-title":"Oncologist"},{"issue":"21","key":"2788_CR64","doi-asserted-by":"crossref","first-page":"4058","DOI":"10.1158\/0008-5472.CAN-22-1731","volume":"82","author":"RB Scharpf","year":"2022","unstructured":"Scharpf RB, Balan A, Ricciuti B, Fiksel J, Cherry C, Wang C, Lenoue-Newton ML, Rizvi HA, White JR, Baras AS. Genomic landscapes and hallmarks of mutant RAS in human cancers. Can Res. 2022;82(21):4058\u201378.","journal-title":"Can Res"},{"issue":"8","key":"2788_CR65","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1089\/thy.2014.0053","volume":"24","author":"EK Jang","year":"2014","unstructured":"Jang EK, Song DE, Sim SY, Kwon H, Choi YM, Jeon MJ, Han JM, Kim WG, Kim TY, Shong YK. NRAS codon 61 mutation is associated with distant metastasis in patients with follicular thyroid carcinoma. Thyroid. 2014;24(8):1275\u201381.","journal-title":"Thyroid"},{"issue":"3","key":"2788_CR66","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2174\/1574892810666150708110816","volume":"10","author":"P Fallahi","year":"2015","unstructured":"Fallahi P, Ferrari M. Cabozantinib in thyroid cancer. Recent Patents Anti-Cancer Drug Discov. 2015;10(3):259\u201369.","journal-title":"Recent Patents Anti-Cancer Drug Discov"},{"issue":"4","key":"2788_CR67","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.apsb.2011.10.007","volume":"1","author":"Y-F Chen","year":"2011","unstructured":"Chen Y-F, Fu L-W. Mechanisms of acquired resistance to tyrosine kinase inhibitors. Acta Pharm Sin B. 2011;1(4):197\u2013207.","journal-title":"Acta Pharm Sin B"},{"issue":"1","key":"2788_CR68","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/CCO.0b013e32835a42b9","volume":"25","author":"MJ Campbell","year":"2013","unstructured":"Campbell MJ, Seib CD, Gosnell J. Vandetanib and the management of advanced medullary thyroid cancer. Curr Opin Oncol. 2013;25(1):39\u201343.","journal-title":"Curr Opin Oncol"},{"issue":"6","key":"2788_CR69","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.3390\/ijms22063031","volume":"22","author":"S Carra","year":"2021","unstructured":"Carra S, Gaudenzi G, Dicitore A, Saronni D, Cantone MC, Plebani A, Ghilardi A, Borghi MO, Hofland LJ, Persani L, et al. Vandetanib versus cabozantinib in medullary thyroid carcinoma: a focus on anti-angiogenic effects in zebrafish model. Int J Mol Sci. 2021;22(6):3031.","journal-title":"Int J Mol Sci"},{"issue":"8","key":"2788_CR70","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1158\/1078-0432.CCR-10-2762","volume":"17","author":"MK Gule","year":"2011","unstructured":"Gule MK, Chen Y, Sano D, Frederick MJ, Zhou G, Zhao M, Milas ZL, Galer CE, Henderson YC, Jasser SA, et al. Targeted therapy of VEGFR2 and EGFR significantly inhibits growth of anaplastic thyroid cancer in an orthotopic murine model. Clin Cancer Res Off J Am Assoc Cancer Res. 2011;17(8):2281\u201391.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"5","key":"2788_CR71","first-page":"2225","volume":"39","author":"SM Ferrari","year":"2018","unstructured":"Ferrari SM, Bocci G, Di Desidero T, Elia G, Ruffilli I, Ragusa F, Orlandi P, Paparo SR, Patrizio A. Piaggi SJOr: Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo. Oncol Rep. 2018;39(5):2225\u201334.","journal-title":"Oncol Rep"},{"issue":"5","key":"2788_CR72","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1200\/JCO.2009.23.6604","volume":"28","author":"SA Wells Jr","year":"2010","unstructured":"Wells SA Jr, Gosnell JE, Gagel RF, Moley J, Pfister D, Sosa JA, Skinner M, Krebs A, Vasselli J, Schlumberger M. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol. 2010;28(5):767.","journal-title":"J Clin Oncol"},{"key":"2788_CR73","first-page":"3459","volume":"9","author":"P Fallahi","year":"2015","unstructured":"Fallahi P, Di Bari F, Ferrari SM, Spisni R, Materazzi G, Miccoli P, Benvenga S, Antonelli A. Selective use of vandetanib in the treatment of thyroid cancer. Drug Des Dev Ther. 2015;9:3459.","journal-title":"Drug Des Dev Ther"},{"issue":"9","key":"2788_CR74","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/S1470-2045(12)70335-2","volume":"13","author":"S Leboulleux","year":"2012","unstructured":"Leboulleux S, Bastholt L, Krause T, de la Fouchardiere C, Tennvall J, Awada A, G\u00f3mez JM, Bonichon F, Leenhardt L, Soufflet C, et al. Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial. Lancet Oncol. 2012;13(9):897\u2013905.","journal-title":"Lancet Oncol"},{"issue":"6","key":"2788_CR75","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1210\/jc.2009-2461","volume":"95","author":"BG Robinson","year":"2010","unstructured":"Robinson BG, Paz-Ares L, Krebs A, Vasselli J, Haddad R. Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Endocrinol Metab. 2010;95(6):2664\u201371.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2788_CR76","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1634\/theoncologist.2008-0261","volume":"14","author":"A Morabito","year":"2009","unstructured":"Morabito A, Piccirillo MC, Falasconi F, De Feo G, Del Giudice A, Bryce J, Di Maio M, De Maio E, Normanno N, Perrone F. Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions. Oncologist. 2009;14(4):378\u201390.","journal-title":"Oncologist"},{"key":"2788_CR77","doi-asserted-by":"crossref","first-page":"6197","DOI":"10.4137\/CMO.S6197","volume":"5","author":"H Deshpande","year":"2011","unstructured":"Deshpande H, Roman S, Thumar J, Sosa JA. Vandetanib (ZD6474) in the treatment of medullary thyroid cancer. Clin Med Insights Oncol. 2011;5:6197.","journal-title":"Clin Med Insights Oncol"},{"issue":"2","key":"2788_CR78","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1200\/JCO.2011.35.5040","volume":"30","author":"SA Wells Jr","year":"2012","unstructured":"Wells SA Jr, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, Baudin E, Elisei R, Jarzab B, Vasselli JR. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol. 2012;30(2):134.","journal-title":"J Clin Oncol"},{"issue":"8","key":"2788_CR79","doi-asserted-by":"crossref","first-page":"4250","DOI":"10.3390\/ijms22084250","volume":"22","author":"K J\u00e1klov\u00e1","year":"2021","unstructured":"J\u00e1klov\u00e1 K, Feglarov\u00e1 T, Rex S, Heger Z, Eckschlager T, Hrab\u011bta J, Hodek P, Kol\u00e1rik M, Indra R. Apoferritin\/vandetanib association is long-term stable but does not improve pharmacological properties of vandetanib. Int J Mol Sci. 2021;22(8):4250.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"2788_CR80","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1038\/sj.bjc.6602461","volume":"92","author":"Y Nobuhara","year":"2005","unstructured":"Nobuhara Y, Onoda N, Yamashita Y, Yamasaki M, Ogisawa K, Takashima T, Ishikawa T, Hirakawa K. Efficacy of epidermal growth factor receptor-targeted molecular therapy in anaplastic thyroid cancer cell lines. Br J Cancer. 2005;92(6):1110\u20136.","journal-title":"Br J Cancer"},{"issue":"24","key":"2788_CR81","doi-asserted-by":"crossref","first-page":"8594","DOI":"10.1158\/1078-0432.CCR-04-0690","volume":"10","author":"BA Schiff","year":"2004","unstructured":"Schiff BA, McMurphy AB, Jasser SA, Younes MN, Doan D, Yigitbasi OG, Kim S, Zhou G, Mandal M, Bekele BN. Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer. Clin Cancer Res. 2004;10(24):8594\u2013602.","journal-title":"Clin Cancer Res"},{"key":"2788_CR82","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1007\/s00280-006-0185-x","volume":"58","author":"J Kurebayashi","year":"2006","unstructured":"Kurebayashi J, Okubo S, Yamamoto Y, Ikeda M, Tanaka K, Otsuki T, Sonoo H. Additive antitumor effects of gefitinib and imatinib on anaplastic thyroid cancer cells. Cancer Chemother Pharmacol. 2006;58:460\u201370.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"8","key":"2788_CR83","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1097\/MLG.0b013e318172aae4","volume":"118","author":"JP Lopez","year":"2008","unstructured":"Lopez JP, Wang-Rodriguez J, Chang CY, Sneh G, Yu MA, Pardo FS, Aguilera J, Ongkeko WM. Gefitinib (Iressa) potentiates the effect of ionizing radiation in thyroid cancer cell lines. Laryngoscope. 2008;118(8):1372\u20136.","journal-title":"Laryngoscope"},{"issue":"10","key":"2788_CR84","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1001\/archotol.133.10.1022","volume":"133","author":"JP Lopez","year":"2007","unstructured":"Lopez JP, Wang-Rodriguez J, Chang C, Chen JS, Pardo FS, Aguilera J, Ongkeko WM. Gefitinib inhibition of drug resistance to doxorubicin by inactivating ABCG2 in thyroid cancer cell lines. Arch Otolaryngol Head Neck Surg. 2007;133(10):1022\u20137.","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"2788_CR85","doi-asserted-by":"crossref","first-page":"101348","DOI":"10.1016\/j.jddst.2019.101348","volume":"55","author":"DH Truong","year":"2020","unstructured":"Truong DH, Le VKH, Pham TT, Dao AH, Pham TPD, Tran TH. Delivery of erlotinib for enhanced cancer treatment: an update review on particulate systems. J Drug Deliv Sci Technol. 2020;55:101348.","journal-title":"J Drug Deliv Sci Technol"},{"issue":"2","key":"2788_CR86","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1177\/1078155208101212","volume":"15","author":"T Hogan","year":"2009","unstructured":"Hogan T, Yu JJ, Williams HJ, Altaha R, Liang X, He Q. Oncocytic, focally anaplastic, thyroid cancer responding to erlotinib. J Oncol Pharm Pract. 2009;15(2):111\u20137.","journal-title":"J Oncol Pharm Pract"},{"issue":"2","key":"2788_CR87","first-page":"473","volume":"30","author":"M Landriscina","year":"2010","unstructured":"Landriscina M, Maddalena F, Fabiano A, Piscazzi A, La Macchia O, Cignarelli M. Erlotinib enhances the proapoptotic activity of cytotoxic agents and synergizes with paclitaxel in poorly-differentiated thyroid carcinoma cells. Anticancer Res. 2010;30(2):473\u201380.","journal-title":"Anticancer Res"},{"issue":"1","key":"2788_CR88","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40164-020-00159-1","volume":"9","author":"V Subbiah","year":"2020","unstructured":"Subbiah V, Dumbrava EI, Jiang Y, Thein KZ, Naing A, Hong DS, Fu S, Piha-Paul SA, Tsimberidou AM, Janku F. Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial. Exp Hematol Oncol. 2020;9(1):1\u20138.","journal-title":"Exp Hematol Oncol"},{"issue":"6","key":"2788_CR89","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1530\/ERC-22-0022","volume":"29","author":"Y-S Choi","year":"2022","unstructured":"Choi Y-S, Kwon H, You M-H, Kim TY, Kim WB, Shong YK, Jeon MJ, Kim WG. Effects of dabrafenib and erlotinib combination treatment on anaplastic thyroid carcinoma. Endocr Relat Cancer. 2022;29(6):307\u201319.","journal-title":"Endocr Relat Cancer"},{"issue":"11","key":"2788_CR90","doi-asserted-by":"crossref","first-page":"250","DOI":"10.3390\/genes11111342","volume":"11","author":"M \u015amiech","year":"2020","unstructured":"\u015amiech M, Leszczy\u0144ski P, Kono H, Wardell C, Taniguchi H. Emerging BRAF mutations in cancer progression and their possible effects on transcriptional networks. Genes. 2020;11(11):250.","journal-title":"Genes"},{"key":"2788_CR91","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1007\/s00268-016-3534-x","volume":"40","author":"S Fraser","year":"2016","unstructured":"Fraser S, Go C, Aniss A, Sidhu S, Delbridge L, Learoyd D, Clifton-Bligh R, Tacon L, Tsang V, Robinson B. BRAF V600E mutation is associated with decreased disease-free survival in papillary thyroid cancer. World J Surg. 2016;40:1618\u201324.","journal-title":"World J Surg"},{"issue":"1","key":"2788_CR92","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12935-017-0457-z","volume":"17","author":"T Notarangelo","year":"2017","unstructured":"Notarangelo T, Sisinni L, Condelli V, Landriscina M. Dual EGFR and BRAF blockade overcomes resistance to vemurafenib in BRAF mutated thyroid carcinoma cells. Cancer Cell Int. 2017;17(1):1\u20139.","journal-title":"Cancer Cell Int"},{"issue":"10","key":"2788_CR93","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1080\/15384047.2018.1480289","volume":"19","author":"T Ofir Dovrat","year":"2018","unstructured":"Ofir Dovrat T, Sokol E, Frampton G, Shachar E, Pelles S, Geva R, Wolf I. Unusually long-term responses to vemurafenib in BRAF V600E mutated colon and thyroid cancers followed by the development of rare RAS activating mutations. Cancer Biol Ther. 2018;19(10):871\u20134.","journal-title":"Cancer Biol Ther"},{"issue":"9","key":"2788_CR94","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/S1470-2045(16)30166-8","volume":"17","author":"MS Brose","year":"2016","unstructured":"Brose MS, Cabanillas ME, Cohen EE, Wirth LJ, Riehl T, Yue H, Sherman SI, Sherman EJ. Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016;17(9):1272\u201382.","journal-title":"Lancet Oncol"},{"issue":"1","key":"2788_CR95","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-017-0548-2","volume":"11","author":"G Shen","year":"2018","unstructured":"Shen G, Zheng F, Ren D, Du F, Dong Q, Wang Z, Zhao F, Ahmad R, Zhao J. Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development. J Hematol Oncol. 2018;11(1):1\u201311.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"2788_CR96","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/s41392-023-01460-1","volume":"8","author":"Z-L Liu","year":"2023","unstructured":"Liu Z-L, Chen H-H, Zheng L-L, Sun L-P, Shi L. Angiogenic signaling pathways and anti-angiogenic therapy for cancer. Signal Transduct Target Ther. 2023;8(1):198.","journal-title":"Signal Transduct Target Ther"},{"key":"2788_CR97","doi-asserted-by":"crossref","first-page":"154809","DOI":"10.1016\/j.cyto.2019.154809","volume":"125","author":"M Puchert","year":"2020","unstructured":"Puchert M, Obst J, Koch C, Zieger K, Engele J. CXCL11 promotes tumor progression by the biased use of the chemokine receptors CXCR3 and CXCR7. Cytokine. 2020;125:154809.","journal-title":"Cytokine"},{"issue":"3","key":"2788_CR98","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/s41416-021-01340-x","volume":"125","author":"J Liang","year":"2021","unstructured":"Liang J, Jin Z, Kuang J, Feng H, Zhao Q, Yang Z, Zhan L, Shen B, Yan J, Cai W. The role of anlotinib-mediated EGFR blockade in a positive feedback loop of CXCL11-EGF-EGFR signalling in anaplastic thyroid cancer angiogenesis. Br J Cancer. 2021;125(3):390\u2013401.","journal-title":"Br J Cancer"},{"issue":"13","key":"2788_CR99","doi-asserted-by":"crossref","first-page":"3567","DOI":"10.1158\/1078-0432.CCR-20-2950","volume":"27","author":"D Li","year":"2021","unstructured":"Li D, Chi Y, Chen X, Ge M, Zhang Y, Guo Z, Wang J, Chen J, Zhang J, Cheng Y. Anlotinib in locally advanced or metastatic medullary thyroid carcinoma: a randomized, double-blind phase IIB trial. Clin Cancer Res. 2021;27(13):3567\u201375.","journal-title":"Clin Cancer Res"},{"key":"2788_CR100","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.3390\/jpm11060559","volume":"11","author":"F Bahman","year":"2021","unstructured":"Bahman F, Pittal\u00e0 V, Haider M, Greish K. Enhanced anticancer activity of nanoformulation of dasatinib against triple-negative breast cancer. J Personal Med. 2021;11:2021.","journal-title":"J Personal Med"},{"issue":"4","key":"2788_CR101","first-page":"807","volume":"3","author":"D Chan","year":"2012","unstructured":"Chan D, Tyner JW, Chng WJ, Bi C, Okamoto R, Said J, Ngan BD, Braunstein GD, Koeffler HP. Effect of dasatinib against thyroid cancer cell lines in vitro and a xenograft model in vivo. Oncol Lett. 2012;3(4):807\u201315.","journal-title":"Oncol Lett"},{"key":"2788_CR102","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3390\/cancers10090278","volume":"10","author":"A Mousson","year":"2018","unstructured":"Mousson A, Sick E, Carl P, Dujardin D, De Mey J, Rond\u00e9 P. Targeting focal adhesion kinase using inhibitors of protein-protein interactions. Cancers. 2018;10:9.","journal-title":"Cancers"},{"issue":"1","key":"2788_CR103","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1476-4598-9-278","volume":"9","author":"D Caccia","year":"2010","unstructured":"Caccia D, Miccich\u00e8 F, Cassinelli G, Mondellini P, Casalini P, Bongarzone I. Dasatinib reduces FAK phosphorylation increasing the effects of RPI-1 inhibition in a RET\/PTC1-expressing cell line. Mol Cancer. 2010;9(1):1\u201314.","journal-title":"Mol Cancer"},{"issue":"10","key":"2788_CR104","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.3390\/cells12101374","volume":"12","author":"EL Bolf","year":"2023","unstructured":"Bolf EL, Beadnell TC, Rose MM, D\u2019Alessandro A, Nemkov T, Hansen KC, Schweppe RE. Dasatinib and trametinib promote anti-tumor metabolic activity. Cells. 2023;12(10):1374.","journal-title":"Cells"},{"key":"2788_CR105","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ctrv.2015.11.003","volume":"42","author":"ME Cabanillas","year":"2016","unstructured":"Cabanillas ME, Habra MA. Lenvatinib: role in thyroid cancer and other solid tumors. Cancer Treat Rev. 2016;42:47\u201355.","journal-title":"Cancer Treat Rev"},{"key":"2788_CR106","doi-asserted-by":"crossref","first-page":"638747","DOI":"10.1155\/2014\/638747","volume":"2014","author":"O Tohyama","year":"2014","unstructured":"Tohyama O, Matsui J, Kodama K, Hata-Sugi N, Kimura T, Okamoto K, Minoshima Y, Iwata M, Funahashi Y. Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models. J Thyroid Res. 2014;2014:638747.","journal-title":"J Thyroid Res"},{"issue":"5","key":"2788_CR107","first-page":"2225","volume":"39","author":"SM Ferrari","year":"2018","unstructured":"Ferrari SM, Bocci G, Di Desidero T, Elia G, Ruffilli I, Ragusa F, Orlandi P, Paparo SR, Patrizio A, Piaggi S. Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo. Oncol Rep. 2018;39(5):2225\u201334.","journal-title":"Oncol Rep"},{"issue":"9","key":"2788_CR108","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1111\/cas.15465","volume":"113","author":"K Ohno","year":"2022","unstructured":"Ohno K, Shibata T. Ito Ki: Epidermal growth factor receptor activation confers resistance to lenvatinib in thyroid cancer cells. Cancer Sci. 2022;113(9):3193\u2013210.","journal-title":"Cancer Sci"},{"issue":"9","key":"2788_CR109","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1080\/13543784.2021.1972971","volume":"30","author":"SM Ferrari","year":"2021","unstructured":"Ferrari SM, Elia G, Ragusa F, Paparo SR, Mazzi V, Miccoli M, Galdiero MR, Varricchi G, Foddis R, Guglielmi G. Lenvatinib: an investigational agent for the treatment of differentiated thyroid cancer. Exp Opin Investig Drugs. 2021;30(9):913\u201321.","journal-title":"Exp Opin Investig Drugs"},{"key":"2788_CR110","doi-asserted-by":"crossref","first-page":"3847","DOI":"10.2147\/CMAR.S188316","volume":"11","author":"M Capozzi","year":"2019","unstructured":"Capozzi M, De Divitiis C, Ottaiano A, von Arx C, Scala S, Tatangelo F, Delrio P, Tafuto S. Lenvatinib, a molecule with versatile application: from preclinical evidence to future development in anti-cancer treatment. Cancer Manag Res. 2019;11:3847.","journal-title":"Cancer Manag Res"},{"issue":"16","key":"2788_CR111","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1002\/cncr.29395","volume":"121","author":"ME Cabanillas","year":"2015","unstructured":"Cabanillas ME, Schlumberger M, Jarzab B, Martins RG, Pacini F, Robinson B, McCaffrey JC, Shah MH, Bodenner DL, Topliss D, et al. A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: a clinical outcomes and biomarker assessment. Cancer. 2015;121(16):2749\u201356.","journal-title":"Cancer"},{"issue":"7","key":"2788_CR112","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1406470","volume":"372","author":"M Schlumberger","year":"2015","unstructured":"Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, Habra MA, Newbold K, Shah MH, Hoff AO, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015;372(7):621\u201330.","journal-title":"N Engl J Med"},{"issue":"19","key":"2788_CR113","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1200\/JCO.19.02654","volume":"38","author":"J Desai","year":"2020","unstructured":"Desai J, Gan H, Barrow C, Jameson M, Atkinson V, Haydon A, Millward M, Begbie S, Brown M, Markman B. Phase I, open-label, dose-escalation\/dose-expansion study of lifirafenib (BGB-283), an RAF family kinase inhibitor, in patients with solid tumors. J Clin Oncol. 2020;38(19):2140.","journal-title":"J Clin Oncol"},{"issue":"15","key":"2788_CR114","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1158\/1078-0432.CCR-22-3613","volume":"29","author":"Y Lin","year":"2023","unstructured":"Lin Y, Qin S, Yang H, Shi F, Yang A, Han X, Liu B, Li Z, Ji Q, Tang L, et al. Multicenter randomized double-blind phase III trial of donafenib in progressive radioactive iodine-refractory differentiated thyroid cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2023;29(15):2791\u20139.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"8","key":"2788_CR115","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.annonc.2023.05.002","volume":"34","author":"AJ Rosenberg","year":"2023","unstructured":"Rosenberg AJ, Liao CY, Karrison T, de Souza JA, Worden FP, Libao B, Krzyzanowska MK, Hayes DN, Winquist E, Saloura V, et al. A multicenter, open-label, randomized, phase II study of cediranib with or without lenalidomide in iodine 131-refractory differentiated thyroid cancer. Ann Oncol. 2023;34(8):714\u201322.","journal-title":"Ann Oncol"},{"issue":"20","key":"2788_CR116","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1056\/NEJMoa2309719","volume":"389","author":"J Hadoux","year":"2023","unstructured":"Hadoux J, Elisei R, Brose MS, Hoff AO, Robinson BG, Gao M, Jarzab B, Isaev P, Kopeckova K, Wadsley J, et al. Phase 3 trial of selpercatinib in advanced RET-mutant medullary thyroid cancer. N Engl J Med. 2023;389(20):1851\u201361.","journal-title":"N Engl J Med"},{"key":"2788_CR117","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.3389\/fonc.2020.01249","volume":"10","author":"W-Q Cai","year":"2020","unstructured":"Cai W-Q, Zeng L-S, Wang L-F, Wang Y-Y, Cheng J-T, Zhang Y, Han Z-W, Zhou Y, Huang S-L, Wang X-W. The latest battles between EGFR monoclonal antibodies and resistant tumor cells. Front Oncol. 2020;10:1249.","journal-title":"Front Oncol"},{"issue":"4","key":"2788_CR118","doi-asserted-by":"crossref","first-page":"499","DOI":"10.3390\/vaccines10040499","volume":"10","author":"B Janani","year":"2022","unstructured":"Janani B, Vijayakumar M, Priya K, Kim JH, Prabakaran D, Shahid M, Al-Ghamdi S, Alsaidan M, Othman Bahakim N, Hassan Abdelzaher M. EGFR-based targeted therapy for colorectal cancer\u2014promises and challenges. Vaccines. 2022;10(4):499.","journal-title":"Vaccines"},{"issue":"2","key":"2788_CR119","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1158\/1078-0432.CCR-05-1325","volume":"12","author":"S Kim","year":"2006","unstructured":"Kim S, Prichard CN, Younes MN, Yazici YD, Jasser SA, Bekele BN, Myers JN. Cetuximab and irinotecan interact synergistically to inhibit the growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice. Clin Cancer Res. 2006;12(2):600\u20137.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"2788_CR120","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.3390\/cancers13112748","volume":"13","author":"ML Uribe","year":"2021","unstructured":"Uribe ML, Marrocco I, Yarden Y. EGFR in cancer: signaling mechanisms, drugs, and acquired resistance. Cancers. 2021;13(11):2748.","journal-title":"Cancers"},{"key":"2788_CR121","doi-asserted-by":"crossref","first-page":"1372553","DOI":"10.3389\/fendo.2024.1372553","volume":"15","author":"M Guo","year":"2024","unstructured":"Guo M, Sun Y, Wei Y, Xu J, Zhang C. Advances in targeted therapy and biomarker research in thyroid cancer. Front Endocrinol. 2024;15:1372553.","journal-title":"Front Endocrinol"},{"key":"2788_CR122","doi-asserted-by":"crossref","first-page":"114500","DOI":"10.1016\/j.ejmech.2022.114500","volume":"238","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Xing Z, Liu T, Tang M, Mi L, Zhu J, Wu W, Wei T. Targeted therapy and drug resistance in thyroid cancer. Eur J Med Chem. 2022;238:114500.","journal-title":"Eur J Med Chem"},{"issue":"1","key":"2788_CR123","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s11523-006-0038-x","volume":"2","author":"R Bianco","year":"2007","unstructured":"Bianco R, Gelardi T, Damiano V, Ciardiello F, Tortora G. Mechanisms of resistance to EGFR inhibitors. Target Oncol. 2007;2(1):31\u20137.","journal-title":"Target Oncol"},{"issue":"28","key":"2788_CR124","doi-asserted-by":"crossref","first-page":"6345","DOI":"10.3748\/wjg.v22.i28.6345","volume":"22","author":"V Sforza","year":"2016","unstructured":"Sforza V, Martinelli E, Ciardiello F, Gambardella V, Napolitano S, Martini G, Della Corte C, Cardone C, Ferrara ML, Reginelli A. Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer. World J Gastroenterol. 2016;22(28):6345.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"2788_CR125","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s12943-018-0793-1","volume":"17","author":"Q Liu","year":"2018","unstructured":"Liu Q, Yu S, Zhao W, Qin S, Chu Q, Wu K. EGFR-TKIs resistance via EGFR-independent signaling pathways. Mol Cancer. 2018;17(1):53.","journal-title":"Mol Cancer"},{"issue":"1","key":"2788_CR126","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1186\/s13046-021-02130-2","volume":"40","author":"J Zhou","year":"2021","unstructured":"Zhou J, Ji Q, Li Q. Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies. J Exp Clin Cancer Res. 2021;40(1):328.","journal-title":"J Exp Clin Cancer Res"},{"issue":"5","key":"2788_CR127","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1097\/MD.0b013e31826a9c71","volume":"91","author":"RP Tufano","year":"2012","unstructured":"Tufano RP, Teixeira GV, Bishop J, Carson KA, Xing M. BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis. Medicine. 2012;91(5):274\u201386.","journal-title":"Medicine"},{"issue":"1","key":"2788_CR128","doi-asserted-by":"crossref","first-page":"e149","DOI":"10.14694\/EdBook_AM.2015.35.e149","volume":"35","author":"R Dienstmann","year":"2015","unstructured":"Dienstmann R, Salazar R, Tabernero J. Overcoming resistance to anti-EGFR therapy in colorectal cancer. Am Soc Clin Oncol Educ Book. 2015;35(1):e149\u201356.","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"9","key":"2788_CR129","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1111\/cas.15465","volume":"113","author":"K Ohno","year":"2022","unstructured":"Ohno K, Shibata T, Ito KI. Epidermal growth factor receptor activation confers resistance to lenvatinib in thyroid cancer cells. Cancer Sci. 2022;113(9):3193\u2013210.","journal-title":"Cancer Sci"},{"issue":"21","key":"2788_CR130","doi-asserted-by":"crossref","first-page":"30907","DOI":"10.18632\/oncotarget.9023","volume":"7","author":"BP Danysh","year":"2016","unstructured":"Danysh BP, Rieger EY, Sinha DK, Evers CV, Cote GJ, Cabanillas ME, Hofmann M-C. Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model. Oncotarget. 2016;7(21):30907.","journal-title":"Oncotarget"},{"issue":"2","key":"2788_CR131","doi-asserted-by":"crossref","first-page":"80","DOI":"10.5306\/wjco.v2.i2.80","volume":"2","author":"F Broekman","year":"2011","unstructured":"Broekman F, Giovannetti E, Peters GJ. Tyrosine kinase inhibitors: Multi-targeted or single-targeted? World J Clin Oncol. 2011;2(2):80\u201393.","journal-title":"World J Clin Oncol"},{"issue":"1","key":"2788_CR132","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3390\/ijms21010010","volume":"21","author":"OV Ancker","year":"2019","unstructured":"Ancker OV, Kr\u00fcger M, Wehland M, Infanger M, Grimm D. Multikinase inhibitor treatment in thyroid cancer. Int J Mol Sci. 2019;21(1):10.","journal-title":"Int J Mol Sci"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-02788-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-025-02788-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-02788-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T08:40:58Z","timestamp":1751532058000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-025-02788-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,2]]},"references-count":132,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["2788"],"URL":"https:\/\/doi.org\/10.1007\/s12032-025-02788-0","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,2]]},"assertion":[{"value":"6 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"233"}}